Emerging treatment options for early mycosis fungoides

Clinical, Cosmetic and Investigational Dermatology

Volumn 6, Issue , 2013, Pages 61-69

  Fernandez Guarino, Montserrat ^a  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

Author keywords

Excimer light; Mycosis fungoides; Photodynamic therapy; Topical treatments

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; IMIQUIMOD; INTERFERON; METHOTREXATE; PSORALEN; RETINOID; TAZAROTENE;

ALOPECIA; ANHIDROSIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; BLISTER; BURN; BURNING SENSATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARBON DIOXIDE LASER; CONTACT DERMATITIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; EARLY MYCOSIS FUNGOIDES; EDEMA; ELECTRON THERAPY; ELECTROSTIMULATION; EROSION; ERYTHEMA; EXCIMER LASER; FLUORESCENCE; GEL; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; INCIDENCE; IRRITANT DERMATITIS; LOW LEVEL LASER THERAPY; MELANOMA; MYCOSIS FUNGOIDES; NAUSEA; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRURITUS; PUVA; REMISSION; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TELANGIECTASIA; ULTRAVIOLET B RADIATION; WHOLE BODY RADIATION; XEROSIS;

EID: 84874363683     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S27482     Document Type: Review

References (60)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
2. van Doorn R, van Haselen CW, van vorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136(4):504-510.
3. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous task force of the European Organization for Research and Treatment of Cancer (EORTC). Blood. 2007;110(6): 1713-1722.
4. Burg G, Dummer R, Haeffner A, Kempf W, Kadin M. From inflammation to neoplasia: mycosis fungoides evolved from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumours. Arch Dermatol. 2001;137(7):949-952.
5. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol. 1995;22(1):11-17.
6. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United Stated Cutaneous Lymphoma Consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607.
7. Ardigò M, Cota C, Berardesca E. Unilesional mycosis fungoides succesfully treated with topical imiquimod. Eur J Dermatol. 2006; 16(4):446.
8. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-1063.
9. Hortwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-442.
10. Dummer R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):72-76.
11. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009;114(20):4337-4353.
12. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination of electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784-1790.
13. Zakheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134(8):949-954.
14. Whittaker SJ, Foss FM. Efficacy and tolerability of currently avalaible therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33(2): 146-160.
15. Heald P, Melhmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801-815.
16. Herman JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2 Pt 1):232-242.
17. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UVB therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999;135(1):1377-1380.
18. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999;141(1):108-112.
19. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med. 1997; 336(15):1041-1045.
20. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130(6):743-751.
21. Boehncke WH, Konig K, Ruck A, Kauffman R, Sterry W. In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. Acta Derm Venereol. 1994;74(3):201-205.
22. Rittenhouse-Diakun K, Van Leengoed H, Morgan J, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-amino-levulinic acid (ALA). Photochem Photobiol. 1995;61(5):523-528.
23. Edstrom DW, Portwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol. 2001;81(3):184-188.
24. Edstrom DW, Ros AM, Parvit A. Topical 5-aminolevulinic acid-based photodynamic therapy for mycosis fungoides: a study of cell proliferation and apoptosis before and after therapy. J Invest Dermatol. 1998;110(4):701.
25. Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid [letter]. J Am Acad Dermatol. 1995;33(3):541.
26. Recio ED, Zambrano B, Alonso ML, et al. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature. Int J Dermatol. 2008;47(4):410-413.
27. Eich D, Eich HT, Otte TH, Ghilescu HG, Stadler R. Photodynamic therapy of cutaneous T cell lymphoma in specific localizations. Hautarzt. 1999;50(2):109-114. German.
28. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol. 1994;31(4):678-680.
29. Wang I, Bauer B, Anderson-Engels S, Svanberg S, Svanberg K. Photodynamic therapy utilizing delta aminolevulinic acid in non-melanoma skins malignancies of the eyelid and periocular skin. Acta Ophthalmol Scand. 1999;77(2):182-188.
30. Orenstein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg. 2000;26(8):765-769.
31. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol. 2001;144(6):1262-1263.
32. Leman JA, Dick DC, Morton CA. Topical 5-ALA therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol. 2002; 27(2):516-518.
33. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004;50(3):363-367.
34. Zane C, Venturini M, Sala R, Calzavara-Pinton P. Photodynamic therapy with mehtylaminolevulinate as a value treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoinmunol Photomed. 2006;22(5):254-258.
35. Fernandez-Guarino M, Harto A, Perez-Garcia B, Montull C, de las Heras E, Jaen P. Plaque-phase mycosis fungoides treated with photodynamic therapy: results in 12 patients. Actas Dermosifiliogr. 2010;101(9):785-791. Spanish.
36. Xiao T, Xia L, Yang ZH, He CD, Gao XH, Chen HD. Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides. Eur J Dermatol. 2008;18(6):660-662.
37. Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol. 2000;136(6):748-752.
38. Passeron T, Zakaria W, Ostovari N, et al. Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides. Arch Dermatol. 2004;140(10):1291-1293.
39. Kontos AP, Kerr HA, Malick F, Fivenson DP, Lim HW, Wong HK. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoinmmunol Photomed. 2006;22(3):168-171.
40. Upjohn E, Foley P, Lane P, et al. Long-term clearance of patch-stage mycosis fungoides with the 308-nm excimer laser. Clin Exp Dermatol. 2007;32(2):168-171.
41. Passeron T, Angeli K, Cardot-Leccia N, Perrin C, Lacour JP, Ortonne JP. Treatment of mycosis fungoides by 308-nm excimer laser: a clinical and histological study in 10 patients. Ann Dermatol Venereol. 2007;134(3 Pt 1):225-231. French.
42. Meisenheimer JL. Treatment of mycosis fungoides using a 308-nm excimer laser: two case studies [letter]. Dermatol Online J. 2006;12(7):11.
43. Jin SP, Jeon YK, Cho KH, Chung JH. Excimer laser therapy (308nm) for mycosis fungoides palmaris et plantaris: a skin-directed and anatomically feasible treatment. Br J Dermatol. 2010;163(3):651-653.
44. Nistico S, Costanzo A, Saraceno R, Chimenti S. Efficacy of monochromatic excimer laser radiation (308nm) in the treatment of early stage mycosis fungoides. Br J Dermatol. 2004;151(4):877-879.
45. Mori M, Campolmi P, Mavilia L, Rossi R, Cappugi P, Pimpinelli N. Monochromatic excimer light (308nm) in patch-stage IA mycosis fungoides. J Am Acad Dermatol. 2004;50(6):943-945.
46. Nistico SP, Saraceno R, Schipani C, Costanzo A, Chimenti S. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg. 2009;27(4):647-654.
47. Goldberg DJ, Stampien TM, Schwartz RA. Mycosis fungoides palmaris et plantaris: successful treatment with the carbon dioxide laser. Br J Dermatol. 1997;136(4):617-619.
48. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27(7):571-577.
49. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007; 157(Suppl 2):8-13.
50. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 2002;138(9): 1137-1139.
51. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003;207(1):116-118.
52. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275-280.
53. Onsun N, Ufacik H, Kural Y, Topcu E, Somay A. Efficacy of imiquimod in solitary plaques of mycosis fungoides. Int J Tissue React. 2005;27(4):167-172.
54. Soler-Machin J, Gilaberte-Calzada Y, Vera-Alvarez J, Coscojuela-Santaliestra C, Martinez-Morales J, Osan-Tello M. Imiquimod in treatment of palpebral micosis fungoides. Arch Soc Esp Oftalmol. 2006;81(4):221-223. Spanish.
55. Chiam LY, Cham YC. Solitary plaque mycosis fungoides of the penis responding to topical imiquimod therapy. Br J Dermatol. 2007;156(3): 560-562.
56. Coors EA, Schuler G, von den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol. 2006; 16(4):391-393.
57. Martinez-Gonzalez MC, Verea-Hernando M, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in micosis fungoides. Eur J Dermatol. 2008;18(2):148-152.
58. Demierre MF, Vachom L, Ho V, Sutton L, Cato A, Leyland-Jones B. Phase 1/2 pilot study of methotrexate-laucopram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol. 2003;139(5):624-628.
59. Apisarthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50(4):600-607.
60. Peycheva E, Daskalow I, Tsoneva I. Electrochemotherapy of mycosis fungoides by interferon-α. Bioelectrochemistry. 2007;70(2): 283-286.